New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 19, 2013
10:36 EDTBAYRY, RHHBYRoche opts not to pursue sale of diabetes device unit, Reuters says
Roche (RHHBY) which had in the past few months considered selling its blood glucose meter business, has decided against putting it up for sale, according to Reuters, citing two people familiar with the matter. The report notes that Bayer (BAYRY) similarly scrapped plans to sell its diabetes device unit this year. Reference Link
News For RHHBY;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:08 EDTBAYRYAmerican Society for Clinical Pharmacology and Therapeutics holds meeting
Subscribe for More Information
February 26, 2015
11:36 EDTBAYRYBayer sees FY15 sales EUR 46
The company expects positive currency effects on sales of about 3% compared with the previous year. Bayer plans to raise EBITDA before special items by a low- to mid-teens percentage, allowing for expected positive currency effects of about 2 percent. Bayer aims to increase core earnings per share by a low-teens percentage, allowing for expected positive currency effects of around 3%.
11:35 EDTBAYRYBayer reports FY14 net income EUR 3.43B vs. EUR 3.19B last year
Subscribe for More Information
06:30 EDTBAYRYBayer says flotation of MaterialScience 'proceeding on schedule'
Subscribe for More Information
February 25, 2015
07:18 EDTRHHBYG Corp to hold annual meeting
Subscribe for More Information
06:14 EDTRHHBYPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
09:06 EDTRHHBYRoche receives orphan status for treatment of pemphigus vulgaris
The FDA granted Roche's Genentech unit orphan status for rituximab, its treatment of pemphigus vulgaris.
07:05 EDTRHHBYRoche and BioMed X enter collaboration agreement to develop sensor technology
Subscribe for More Information
February 23, 2015
06:21 EDTRHHBYFacebook's shuttle drivers approve new union contract, WSJ reports
Subscribe for More Information
February 20, 2015
16:48 EDTRHHBYDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
07:23 EDTRHHBY, BAYRYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
06:29 EDTBAYRYBayer close to selling diabetes unit to Panasonic, Bloomberg says
Subscribe for More Information
February 19, 2015
18:25 EDTBAYRY, RHHBYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
16:50 EDTBAYRYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
14:53 EDTBAYRYBayer near sale of diabetes unit to KKR backed venture, Bloomberg says
Subscribe for More Information
14:01 EDTBAYRYBayer near sale of diabetes unit to KKR's Panasonic Healthcare, Bloomberg says
Subscribe for More Information
09:09 EDTRHHBYLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
06:45 EDTRHHBYStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
05:31 EDTRHHBYExelixis announces acceptance of NDA for Genentech cobimetinib
Subscribe for More Information
05:26 EDTRHHBYFDA grants Genentech cobimetinib priority review for combination use
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use